Skip to main content
. 2020 Nov;9(11):6963–6987. doi: 10.21037/tcr-20-2303

Figure 1.

Figure 1

Flow chart. RCT, randomized controlled trial; RWS, real-world studies; BEV, bevacizumab; CET, cetuximab; XELOX, oxaliplatin combined with capecitabine.